MIRM vs. ICPT, CDMO, UROV, NGM, DRRX, ALPN, NUVL, ALKS, PRGO, and CRNX
Should you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Intercept Pharmaceuticals (ICPT), Avid Bioservices (CDMO), Urovant Sciences (UROV), NGM Biopharmaceuticals (NGM), DURECT (DRRX), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector.
Intercept Pharmaceuticals (NASDAQ:ICPT) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
In the previous week, Mirum Pharmaceuticals had 8 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 1 mentions for Intercept Pharmaceuticals. Intercept Pharmaceuticals' average media sentiment score of 0.93 beat Mirum Pharmaceuticals' score of 0.30 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.
83.8% of Intercept Pharmaceuticals shares are held by institutional investors. 6.2% of Intercept Pharmaceuticals shares are held by company insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Intercept Pharmaceuticals has higher revenue and earnings than Mirum Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Intercept Pharmaceuticals has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Intercept Pharmaceuticals presently has a consensus price target of $19.00, indicating a potential upside of 0.00%. Mirum Pharmaceuticals has a consensus price target of $49.73, indicating a potential upside of 106.94%. Given Intercept Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Intercept Pharmaceuticals.
Intercept Pharmaceuticals received 956 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 72.37% of users gave Mirum Pharmaceuticals an outperform vote while only 72.27% of users gave Intercept Pharmaceuticals an outperform vote.
Intercept Pharmaceuticals has a net margin of -19.39% compared to Intercept Pharmaceuticals' net margin of -69.67%. Intercept Pharmaceuticals' return on equity of -56.46% beat Mirum Pharmaceuticals' return on equity.
Summary
Mirum Pharmaceuticals beats Intercept Pharmaceuticals on 12 of the 19 factors compared between the two stocks.
Get Mirum Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mirum Pharmaceuticals Competitors List
Related Companies and Tools
